ENvue Medical Inc (FEED) is a medical device company that is developing and seeking to commercialize medical device product candidates. The company was formerly known as NanoVibronix, Inc. and adopted its current name following a merger completed on February 14, 2025, in which it acquired ENvue Medical Holdings LLC. Revenue generation from commercial products had not been established as of the fiscal year ended December 31, 2024, and management disclosed substantial doubt about the company's ability to continue as a going concern in the 10-K filed April 15, 2026. The company depends on raising additional capital to fund clinical trials and product development, and expects to continue incurring losses. Third-party reimbursement from Medicare, Medicaid, and commercial insurers is identified as a key condition for any future commercially viable market for its products.
The company is developing medical device product candidates. Specific product names, indications, or development-stage details are not described in the available filing excerpts.
The company had not demonstrated a commercial revenue model as of FY2024. Future revenue, if achieved, is expected to depend on product sales through direct or third-party distribution channels, with reimbursement from third-party payers including Medicare, Medicaid, and commercial insurers described as necessary for commercial viability.
The end market is healthcare, with patients and healthcare providers as the ultimate customers. Third-party payers including Medicare, Medicaid, and commercial insurers are identified as gatekeepers for product reimbursement. The company is subject to HIPAA and GDPR regulations, indicating potential handling of patient health information.
The filing references U.S. federal healthcare regulations as primary compliance obligations, with additional references to EU GDPR and foreign data protection laws, suggesting at least anticipated international operations. Specific revenue by geography is not disclosed in the available excerpts.
Loading...